Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Acute respiratory failure occurs in up to half of patients with haematological malignancies and 15% of those with solid tumours or solid organ transplantation. Mortality remains high. Factors associated with mortality include a need for invasive mechanical ventilation, organ dysfunction, older age, frailty or poor performance status, delayed intensive care unit admission, and acute respiratory failure due to an invasive fungal infection or unknown cause. In addition to appropriate antibacterial therapy, initial clinical management aims to restore oxygenation and predict the most probable cause based on variables related to the underlying disease, acute respiratory failure characteristics, and radiographic findings. The cause of acute respiratory failure must then be confirmed using the most efficient, least invasive, and safest diagnostic tests. In patients with acute respiratory failure of undetermined cause, a standardised diagnostic investigation should be done immediately at admission before deciding whether to perform more invasive diagnostic procedures or to start empirical treatments. Collaborative and multidisciplinary clinical and research networks are crucial to improve our understanding of disease pathogenesis and causation and to develop less invasive diagnostic strategies and more targeted treatment options.

Epidemiology

The incidence of respiratory events varies across different groups of immunocompromised patients (table 1). Few studies have followed cohorts of patients with the main objective of collecting information about the incidence of pulmonary infiltrates or respiratory complications. Observational studies have shown that among haematological malignancies, lymphoproliferative disorders (acute lymphoblastic leukaemia and lymphoma) were associated with a moderate incidence of respiratory events (8–18%) compared with acute myeloid leukaemia and myelodysplastic syndromes (22–84%; table 1). Immunosuppressed patients with acute respiratory failure require oxygen therapy and most studies of acute respiratory failure included patients receiving ≥6 L/min of standard oxygen. However, depending on the country and number of available hospital beds, patients with acute respiratory failure can be managed on wards, in intermediate care units, or in intensive care units (ICUs). Overall, the need for ICU admission, need for invasive mechanical ventilation (IMV), or mortality increase with the required oxygen flow. Thus, for patients that require 6 L/min of standard oxygen or more, need for intubation throughout the ICU stay and mortality before hospital discharge are up to 40%. Delayed ICU admission has been associated with increased mortality.

Immunocompromised patients with acute respiratory failure can be encountered by all clinicians in their daily practice. In this Review, we look at the epidemiology, outcomes, and diagnostic investigations in immunocompromised patients with acute respiratory failure, with emphasis on the broad range of causes that must be considered. We discuss the role for invasive and non-invasive tests in identification of the cause of acute respiratory failure, although the huge diversity of tests available for each cause, coupled with the scarcity of randomised controlled trials, creates major challenges. We also suggest an approach to the management of hypoxaemia based on the latest literature.

Key messages

• Acute respiratory failure occurs in up to 50% of haematology patients (primarily patients with acute myeloid leukaemia or allogeneic haemopoietic stem cell transplantation) and in up to 15% of patients with solid tumours (chiefly lung cancer) or solid organ transplants (chiefly of the heart or lung).
• Mortality is high and is associated with invasive mechanical ventilation and organ dysfunction; older age; frailty or poor performance status; delayed intensive care unit admission; and acute respiratory failure due to an invasive fungal infection or unknown cause.
• In addition to appropriate antibacterial therapy, initial management aims to restore oxygenation and predict the most probable cause on the basis of variables related to the underlying disease, the characteristics of acute respiratory failure, and the radiographic findings. The cause of acute respiratory failure must then be confirmed using the most efficient, least invasive, and safest diagnostic tests.
• In patients with acute respiratory failure of undetermined cause, a standardised diagnostic investigation should be done immediately at admission before deciding whether to perform more invasive diagnostic procedures or to start empirical treatments.
• Collaborative and multidisciplinary clinical and research networks are crucial both to improve our understanding of disease pathogenesis and causation and to develop less invasive diagnostic strategies and more targeted treatment options.
Moreover, patients with prolonged neutropenia and autologous or allogeneic stem cell transplant recipients have higher incidences of respiratory events compared with other haematology patients. Solid tumours are associated with a lower incidence of respiratory events than haematological malignancies, with lung cancer having the highest rates (up to 50%), because endobronchial obstruction and atelectasis are risk factors for pneumonia. However, in patients with breast cancer treated with radiation and paclitaxel, the crude rate of pneumonitis was 14-6% (95% CI 5.6–29.2). Of note, in patients with cancer receiving immunotherapy (mostly with programmed death 1 and programmed death ligand 1 inhibitors), the incidence of pneumonitis can reach 4%. Acute respiratory failure occurs in about 5% of kidney transplant recipients and 12–14% of heart or lung transplant recipients. Overall, mortality among patients with acute respiratory failure is about 50%, depending on the underlying condition, nature, severity, and course of the respiratory failure, need for IMV, and associated organ dysfunctions.

Factors associated with mortality
Several studies have assessed risk factors for mortality in immunocompromised patients with acute respiratory failure. These factors can be grouped into five categories: (1) factors reflecting the severity of the acute respiratory failure and associated organ dysfunctions, (2) factors related to delayed ICU admission, (3) factors related to the underlying disease and comorbid conditions, (4) factors related to the initial oxygenation and ventilation strategy, and (5) factors related to the cause of acute respiratory failure.

### Table 1: Incidence of respiratory events in various types of immunocompromised patients

| Category                                      | Incidence of respiratory events | Need for ICU admission | Hospital mortality |
|-----------------------------------------------|---------------------------------|------------------------|--------------------|
| **Haematological malignancies**               |                                 |                        |                    |
| Acute myeloid leukaemia14–19                   | 22–84%                          | 66%                    | 45%                |
| Acute lymphoblastic leukaemia10,13           | 7–18.5%                         | 12–15%                 | 38.5%              |
| Lymphoproliferative diseases4                 | 8%                              | 8%                     | 40–50%             |
| Myelodysplastic syndrome29                    | 29.4%                           | 20%                    | 17%                |
| Autologous haemopoietic stem cell therapy42,5 | 3–28%                           | 42%                    | 3–55%              |
| Allogeneic haemopoietic stem cell therapy6,7  | 24–30%                          | 50%                    | 51%                |
| Prolonged neutropenia8,30                     | 8–29.5%                         | 11–16%                 | 5–12%              |
| **Solid tumours**                             |                                 |                        |                    |
| Lung cancer25,30                               | 26–50%                          | 100%                   | 11.2–60%           |
| Other solid tumours25,30                      | 0.7–10.3%                      | 100%                   | 6.1–55%            |
| Patients on immunotherapy26,27                | 1.3–3.6%                        | 1.3%*                  | n. s.              |
| **Solid organ transplantation**               |                                 |                        |                    |
| Lung transplantation11                         | 14%                             | All                    | 65%                |
| Heart transplantation12                        | 12.5%                           | All                    | 76.5%              |
| Kidney transplantation12,13                    | 3.3–4.8%                       | All                    | 16.4–22.5%         |

Data on patients with drug-related immunosuppression are sparse. *Refers to grade 3-4 toxicities. ICU=intensive care unit.

Hypoaxaemia is the hallmark of respiratory failure. The clinical signs and tolerance of hypoaxaemia are usually a function of respiratory symptom duration. For instance, an acute hypoaxaemic episode can lead to respiratory distress within a few hours, whereas a subacute or non-acute lung insult of similar magnitude can result in deep hypoaxaemia without signs of respiratory distress. Overall, degree of hypoaxaemia reflects the extent of lung involvement. Hypoaxaemia, measured directly as the PaO2 on room air or assessed on the basis of the oxygen flow needed to achieve an peripheral capillary oxygen saturation (SpO2) of 95% of the estimated or calculated ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/FiO2 ratio), has been used for many years to risk-stratify patients and guide ICU admission decisions. Increased oxygen flow has been associated with the need for ICU admission, need for IMV, and hospital mortality. Similarly, lower PaO2/FiO2 has been associated with mortality in patients with acute respiratory distress syndrome, the need for non-invasive ventilation (NIV), or failure of high-flow nasal oxygen therapy (HFNO). Persistent tachypnoea has also been associated with failure of standard oxygen, NIV, or high-flow nasal cannula, requiring the implementation of another strategy (eg, intubation). No study has evaluated the impact of hyperoxygenation in this setting. Associated organ dysfunctions are best depicted by the Sequential Organ Failure Assessment (SOFA) score, which has consistently been identified as a determinant of mortality, with higher scores associated with increased mortality.

Delayed ICU admission has been associated with increased mortality in immunocompromised patients, particularly in those with acute respiratory failure. Benefits from earlier ICU admission might be the result of the careful clinical assessment, optimal oxygenation strategy, avoidance of potentially harmful investigations, and selection of the least invasive diagnostic tests in ICUs. The characteristics of the underlying immunosuppressive condition are not usually associated with hospital mortality following ICU admission, although variations occur depending on ICU admission policies. A higher proportion of patients admitted to ICU with do-not-resuscitate or do-not-intubate status results in stronger associations between variables reflecting characteristics of disease status and mortality. Performance status and comorbidities have been associated with increased mortality. The effects of initial oxygenation and ventilation strategy on mortality are discussed later in this Review. Furthermore, as previously mentioned, several studies have assessed the association between the cause of acute respiratory failure and mortality. Mortality is lowest in patients with cardiac pulmonary oedema and highest in those with invasive fungal infections or no identified cause of acute respiratory failure.

**Early assessment of pre-test probability of acute respiratory failure cause**

One of the first and key steps in the early management of immunocompromised patients with acute respiratory
failure is to establish the probable cause of acute respiratory failure, at the bedside, based on clinical examination before undertaking tests. No standard combination therapy is suitable for all patients with acute respiratory failure; each patient must be considered individually. Clinicians should make every effort to identify the cause of acute respiratory failure in patients at high risk of intubation and mortality (eg, those with a higher SOFA score or more hypoaemic). Bacterial infection is the main cause of acute respiratory failure, and up to 90% of patients receive antibacterial drugs soon after admission. Cardiogenic pulmonary oedema must be considered in every patient. However, other diagnoses should be considered on a case-by-case basis. Thus, the basic diagnostic investigation is the same for all patients (panel 1). It includes tests for cardiogenic pulmonary oedema, sputum examination, and blood cultures to detect bacterial or fungal infections, induced sputum examination for *Pneumocystis*, viral multiplex PCR on nasopharyngeal aspirates or swabs, viral PCR on plasma or blood, an assessment of the likelihood that the underlying condition and its treatments will affect the lungs, and an analysis of the imaging data.

When performing the first clinical examination, the mnemonic DIRECT can be used to assess the cause of acute respiratory failure at the bedside. D refers to respiratory symptom duration in days, I to the type of immunosuppression, R to the chest X-ray pattern, E to the clinician’s experience of similar cases, C to the clinical findings, and T to high-resolution CT. In patients with myeloproliferative diseases such as acute myeloid leukaemia, myelodysplastic syndrome, or chronic myeloid leukaemia, most cases of acute respiratory failure that occur early after disease onset are related to leukaemic infiltrates (figure I), although some patients might present with pneumonia or cardiogenic pulmonary oedema. Acute respiratory failure of infectious origin is, however, more common at the earliest phase of lymphoproliferative disorders (figure I), such as acute lymphoblastic leukaemia or lymphoma. In patients with T-cell proliferations, opportunistic infections have been reported before cancer treatment initiation, exemplifying the role played by disease-related immunosuppression. Later, during follow-up, infection is the main cause (figure I), although treatment-related toxicities and disease relapse can also lead to acute respiratory failure. Clinicians can struggle with non-infectious causes whose diagnosis is believed to rely solely on biopsies, which are difficult to obtain in hypoaemic patients with thrombocytopenia and haemostatic disorders, or on bronchoscopy and bronchoalveolar lavage, and have been reported as possibly deteriorating the respiratory status and increasing IMV needs. However, a multidisciplinary and collaborative approach allows earlier recognition of typical patterns of clinical and laboratory findings, for which no additional diagnostic procedures are needed (lung infiltration by the underlying condition, leukaemic infiltrates in patients with acute myeloid leukaemia, diffuse alveolar haemorrhage, cytarabine-related pulmonary toxicity, immunotherapy-related pneumonitis, etc). Patients with these patterns are often considered to have no known cause of acute respiratory failure until a multidisciplinary team makes the appropriate diagnosis. Similarly, conditions such as neutropenia or allogeneic haemopoietic stem cell transplantation are associated with both a high risk of respiratory events and specific acute respiratory failure causes such as exacerbation of previous lung injury during neutropenia recovery, or non-infectious interstitial lung diseases following haemopoietic stem cell transplantation.

Acute respiratory failure in the first few days after solid organ transplantation is probably related to either a

---

### Panel 1: Basic diagnostic investigations to be applied to all immunocompromised patients presenting with acute respiratory failure

Tests to diagnose or rule out cardiogenic pulmonary oedema
- Echocardiography
- Biomarkers such as natriuretic peptide or N-terminal pro b-type natriuretic peptide could be used in the emergency department to rule out cardiogenic pulmonary oedema for their good negative predictive value

Sputum examination to detect bacterial (and mycobacterial) infections

Blood cultures to detect bacterial or fungal infections

Urine antigen for *Legionella pneumophilia* and *Streptococcus pneumoniae*
- Induced sputum examination for *Pneumocystis jiroveci* pneumonia. Both classic staining, immunofluorescence, and PCR can be useful on induced sputum

Induced sputum is performed after inhalation (during 15–20 min) of nebulised sterile hypertonic saline solution followed by coughing and expectoration of airway secretions. In patients with severe chronic obstructive pulmonary disease or asthma, pre-treatment with inhaled salbutamol and monitoring of lung function during the procedure are needed

Viral multiplex PCR on nasopharyngeal aspirates or nasal swabs to detect respiratory viruses (adenovirus, metapneumovirus, some types of coronavirus, parainfluenza virus types 1, 2, 3, and 4, influenza virus types A and B, respiratory syncytial virus A and B, rhinovirus A, B, and C, bocavirus, and enterovirus). This test also detects *L pneumophila, Mycoplasma pneumoniae*, and *Chlamydia pneumoniae*

Viral PCR on plasma or blood to detect herpesviruses (including *cytomegalovirus*).

Other PCR tests: although the results of most PCR methods lack specificity for the detection of *Aspergillus* sp, PCR allows early detection of other fungi (eg, *Mucorales*) or parasites (eg, *Toxoplasma gondii*

**Biomarkers**
- Procalcitonin has limited predictive value in immunocompromised patients
- Serum *Aspergillus galactomannan* is useful for the detection of both invasive aspergillosis and histoplasmosis
- Serum 1,3 β-D-glucan for all fungal infections except mucormycosis

**Echography-guided pleurocentesis** (check platelet count and haemostasis)

**Biopsy or puncture of extra-pulmonary involvement** (skin, joints, peripheral lymph nodes, sternal puncture, buccal smear, etc)

**Imaging data**, including chest X-ray, lung and pleural echography, and high-resolution CT scan (without first-line contrast media unless there is a clinical suspicion of pulmonary vascular disease)
surgical complication or to decompensation of a chronic respiratory or cardiac comorbid condition. Invasive candidiasis might occur quite early after transplantation. However, most opportunistic infections are reported more than 3 months after transplantation and depend heavily on adherence to prophylactic regimens by the patient. Of note, with the use of intensive immunosuppression in patients experiencing acute humoral or interstitial rejection and with the use of immunosuppressant drug combinations to ensure graft tolerance, clinicians must carefully assess the individual risk for each possible cause and perform a complete diagnostic investigation.

In each individual case, the type of immune deficiency must be assessed to allow appropriate adjustment of the initial anti-infectious treatment (figure 2) to avoid treatment delays. Imaging studies, particularly high-resolution CT, are another important bedside tool for determining the cause of acute respiratory failure. This Review does not detail the radiological findings in immunocompromised patients with acute respiratory failure. Patterns of lung involvement are an important piece of the puzzle but are not predictive of a specific cause. However, a combination of positive and negative high-resolution CT findings suggest specific causes of lung infiltrates. Different components of the DIRECT mnemonic contribute to determining the pre-test clinical probability for each individual diagnosis (figure 3). A given clinical situation can be related to different causes of acute respiratory failure, because contextual elements and clinical findings vary across patients. However, the administration of antifungal drugs or anti-Pneumocystis therapy should not be delayed if the pre-test probability of the disease is substantial.

Avoiding situations in which the acute respiratory failure cause remains undetermined

Non-invasive diagnostic tests offer an alternative to bronchoscopy and bronchoalveolar lavage, which carry a risk of respiratory deterioration requiring IMV. However, bronchoalveolar lavage might be required when non-invasive respiratory samples are either not feasible or of poor quality. Performing bronchoalveolar lavage with the support of NIV or high-flow nasal cannula can help patients tolerate the procedure. Also, first-line bronchoalveolar lavage might be required when the acute respiratory failure cause remains undetermined.
Diagnoses such as bacterial infection, pulmonary oedema, and alveolar haemorrhage need to be ruled out or treated in every case. BAL = bronchoalveolar lavage.

Figure 3: Five clinical vignettes for which the application of the DIRECT mnemonic leads to different diagnostic probabilities

**Patient presentation**

- Acute respiratory failure, severe hypoaemia and diffuse alveolar-interstitial infiltrates within 7 days of a new haematological diagnosis
- Acute respiratory failure 14 months after kidney transplantation. No extra-pulmonary symptoms. Fever.
- Acute onset of respiratory distress with fever and hypotension in an immunocompromised patient. Focal or diffuse alveolar consolidation.
- Acute respiratory failure in a patient with ischaemic cardiopathy treated with PD-1 inhibitors for metastatic melanoma for 4 months. Bilateral ground-glass opacities on CT.
- Severe respiratory distress in a patient with long-term steroids and immunosuppressant for severe Cohn’s disease. CT scan discloses ill-defined consolidations and cavitations in both lungs.

**Diagnostic options after application of DIRECT**

- If untreated hairy cell leukaemia, consider intra-cellular pathogens (Legionella, influenza, filamentous fungi) as possible source of infection.
- If hyperleukocytic acute myeloid leukaemia (200 000 cells per L) treated for 3 days, consider acute lysis pneumopathy.
- If untreated acute myeloid leukaemia, consider leukaemic infiltrates such as infiltration or leukostasis.
- If no prophylaxis, very high probability of Pneumocystis jirovecii pneumonia.
- If patient taking aspirin and anticoagulants, exclude overdose and diffuse alveolar haemorrhage. Perform BAL.
- If patient has myeloma and hypo-gammaglobulinaemia, give priority to bacterial infection.
- If lung cancer patient with neutropenia, give priority to bacterial infection.
- If patient has myeloma and hypo-gammaglobulinaemia, give priority to bacterial infection.
- If patient taking aspirin and anticoagulants, exclude overdose and diffuse alveolar haemorrhage. Perform BAL.
- If patient has myeloma and hypo-gammaglobulinaemia, give priority to bacterial infection.
- If patient has myeloma and hypo-gammaglobulinaemia, give priority to bacterial infection.

Figure 2: Risk for specific pathogens according to the type of haematological malignancy or treatment

This figure illustrates the most frequently encountered types of infection according to the main disease-related or treatment-related immunological deficiency. It focuses mainly on secondary immunosuppression in adults, as data for primary immune deficiencies are scarce.

**Immunological deficiency**

- Neutrophils
- Monocytes/dendritic cells/macrophages
- B lymphocytes
- T lymphocytes
- Humoral (antibody) immunity

**Diseases**

- Acute leukaemia, myelodysplastic syndrome, aplastic anaemia, chemotherapy and drug-related neutropenia
- Hailey cell leukaemia, aplastic anaemia, allo-genic bone marrow transplant; malignant histiocytosis; acute myeloid leukaemia; chronic myeloid leukaemia; solid tumours; haemophagocytic lymphohistiocytosis
- Multiple myeloma, B-cell lymphoma, chronic lymphocytic leukaemia
- T-cell leukaemia, T-cell lymphoma
- Multiple myeloma, chronic lymphoid leukaemia

**Treatments**

- Chemotherapy-induced neutropenia
- Steroids, basiliximab, anthracytomyse globulin, tacrolimus, mycophenolate mofetil, belatacept
- Chemotherapy, steroids, asplenia, rituximab
- Steroids, fludarabine, cyclophosphamide, methotrexate, azathioprine, almitizumab, mycophenolate mofetil, cyclosporine, mTOR inhibitors (sirolimus), tacrolimus, 2-chlorodeoxyadenosine, daratumumab
- Brutinib, rituximab, daratumumab, cyclophosphamide

**Most frequently encountered infections**

- Gram-negative bacteria
- Gram-positive bacteria
- Candida
- Aspergillus
- Nocardia
- Non-tuberculous mycobacteria
- Salmonella, Liston, Legionella, Histoplasme, Brucella
- Herpes simplex virus, varicella zoster virus, parainfluenza virus, respiratory syncytial virus
- Candida parapsilosis
- Staphylococcus aureus, Enterocosus faecalis, Pseudomonas aeruginosa
- Encapsulated bacteria
- Pseudomonas, streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae
- Giardia lamblia, Cryptosporidium, Salmonella
- Mycoplasma
- Enterovirus
- Recurrent infections
- Herpes simplex virus, cytomegalovirus, Epstein-Barr virus
- Pneumocystis, Aspergillus, Cryptococcus
- Mycobacterial infection
- Skin candidiasis
- Diarrhoea (rotaviruses, adenoviruses, Cryptosporidium, microsporidia, etc)
- John Cunningham virus
- Encapsulated bacteria
- S pneumoniae, S pyogenes, H influenzae
- Mycoplasma, Ureaplasma urealyticum
- Other infections related to associated T-cell defects

**Examinations, treatments, and biomarkers**

- Cultures, serum and urine antigen assays, imaging studies, and biomarker assays. These non-invasive tests perform as well as bronchoscopy and bronchoalveolar lavage. In solid organ transplant recipients, however, bronchoalveolar lavage has a higher diagnostic yield, although the risk–benefit ratio has not been assessed in this population. Moreover, with the advent of omics to assist in the diagnosis of infections, as well as sophisticated immunology and molecular biology methods and advances in imaging techniques to establish the diagnosis of non-infectious conditions, a reappraisal of the diagnostic yield of non-invasive tests in immunocompromised patients is warranted. Nevertheless, despite an optimal early diagnostic investigation, the cause remains undetermined in 10–15%
Review

of patients with acute respiratory failure (figure 4; table 2). Failure to identify the cause of acute respiratory failure was independently associated with mortality in several studies. Failure to identify the cause of acute respiratory failure was independently associated with mortality in several studies. In some patients, the cause of acute respiratory failure is identified late, and the impact of a late diagnosis and correspondingly late treatment has not been assessed. The association between absence of a documented cause and mortality raises several questions.

Figure 4: Causes of pulmonary infiltrates in immunocompromised patients with acute respiratory failure
Mean percentage is reported in the first column in red for each cause, with 95% confidence intervals reported underneath. The study by Gruson and colleagues included only bone marrow transplant recipients and the studies by Wohlfarth and colleagues and Schmidt and colleagues included only patients with severe acute respiratory distress syndrome treated with extra-corporeal membrane oxygenation.

| N | Cause of immunosuppression | Intubated (%) | Mortality (%) | Underwent bronchoalveolar lavage (%) |
|---|--------------------------|--------------|--------------|-------------------------------------|
| | | All | O₂ | NIV | HFNO | All | O₂ | NIV | HFNO | All | O₂ | NIV | HFNO |
| Antonelli et al<sup>5</sup> | 40 | Solid organ transplants | 33.7 | 70 | 20 | .. | 35 | 50 | 20 | .. | 27.5 | 0 |
| Hilbert et al<sup>5</sup> | 52 | All types | 61.5 | 66 | 46.1 | .. | 53.8 | 80.8 | 50 | .. | 32.7 | .. |
| Azoulay et al<sup>9</sup> | 203 | Oncology and haematology patients | 85.0 | .. | 57 | .. | 56.9 | 48.1 | .. | 72 | 20.7 |
| Lemiale et al<sup>11</sup> | 380 | Haematology patients | 24.7 | 20 | 32 | .. | 32.6 | 26 | 44 | .. | .. | 24.7 |
| Lemiale et al<sup>11</sup> | 374 | All types | 41.4 | 45 | 38.2 | .. | 25.7 | 34.4 | 30.9 | .. | 38 | 4.5 |
| Mokart et al<sup>12</sup> | 178 | Oncology and haematology patients | 48.0 | 50 | 45.9 | 75 | 46 | 55 | 56 | 25 | .. | 25 |
| Frat et al<sup>12</sup> | 82 | All types | 46.3 | 43 | 65 | 31 | 29.3 | 27 | 46.1 | 15 | .. | 4.9 |
| Coudroy et al<sup>15</sup> | 115 | All types | 44.0 | .. | 55 | 35 | 30 | .. | 40 | 20 | .. | .. |
| Lemiale et al<sup>11</sup> | 353 | All types | 40.2 | 38 | .. | 45 | 22.6 | 20.7 | .. | 25.9 | 38.2 | 4.5 |
| Azoulay et al<sup>13</sup> | 161 | All types | 40.9 | 41 | 41 | 41 | 36.5 | 32.7 | 36.9 | 38.4 | 60 | 12.9 |
| Tu et al<sup>19</sup> | 38 | Solid organ transplants | 34.2 | .. | 50 | 20 | 22.7 | .. | 22.2 | 5 | .. | .. |
| Total | 3426 | .. | 45.0 | 47 | 45 | 41 | 35 | 37 | 40 | 21 | 45 | 12 |

Only studies published in English from Jan 1, 1998, to April 30, 2018, were taken into account. Studies that comprised only postoperative patients and studies on palliative NIV were not included. NIV=non-invasive ventilation. HFNO=high-flow nasal oxygen therapy. *Randomised controlled trials. †Post-hoc analysis of randomised controlled trials. ‡Indicates day-90 mortality; all other studies reported hospital mortality.

Table 2: Studies reporting intubation and mortality in immunocompromised patients receiving standard oxygen, non-invasive ventilation, or high-flow nasal oxygen therapy.
thrombocytopenia or other severe haemostatic abnormalities. Data on surgical lung biopsies in this setting are, therefore, scarce (table 4). Nevertheless, valuable information can be gleaned from studies reporting surgical lung biopsy or autopsy data in immunocompromised patients with acute respiratory failure of unknown cause. Overall, lung biopsy had a diagnostic yield above 60%, with complications in 10% of patients, despite careful patient selection for the procedure. Lung biopsy had a lower diagnostic yield in patients receiving IMV. Invasive fungal infections and malignant or potentially steroid-sensitive lung infiltrates were the most common causes of acute respiratory failure (table 4). The diagnostic yield of surgical lung biopsy for unexplained pulmonary infiltrates was assessed in a retrospective study of 62 haematology patients. The exact diagnosis was established in 67% of patients, with invasive aspergillosis and malignancy being the main causes. The biopsy result prompted a treatment change in 40% of patients, and complications occurred in 11% of patients. The diagnostic yield was lower in patients

| Unidentified, unsuspected, and untreated condition | Unidentified, suspected, but suboptimally treated condition | Undocumented coinfection in which one pathogen remains untreated | Infectious and non-infectious condition, of which one is unidentified or untreated | Identified aetiology mistakenly considered as irrelevant finding |
|---------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Actual underlying cause | | | | |
| Incorrectly presumed cause | | | | |
| Procedure that should have been performed | | | | |
| Missed treatment | | | | |

Table 3: Hypothetical examples of causes of increased mortality when the cause of acute respiratory failure is not identified

---

**Figure 5**: First-line diagnostic strategy according to clinical and radiographic presentation

ICU=intensive care unit. HSCT=haemopoietic stem cell therapy. GVHD=graft versus host disease. CRP=C-reactive protein. PCT=procalcitonin. BAL=bronchoalveolar lavage.

---

www.thelancet.com/respiratory Vol 7 February 2019
with acute respiratory failure who were receiving IMV at the time of biopsy than in non-intubated patients. In a cohort of 63 haematology patients, the diagnostic yield of lung biopsy was 62% and the therapeutic yield 57%. The diagnostic yield was lower in patients on IMV and in those with neutropenia, but was higher in patients with focal infiltrates. Invasive aspergillosis was also a common biopsy finding in this study. Complications occurred in 13% of patients. The 15% prevalence of invasive aspergillosis is in line with data on acute respiratory distress syndrome in patients with cancer40 and with autopsy findings in patients with acute respiratory distress syndrome. In 21 haematology patients, including 10 in whom the lung biopsies were obtained post-mortem, inflammatory and malignant infiltrates were the most common diagnoses. A retrospective autopsy study of 7 haemopoietic stem cell transplant recipients showed that fungal infections, potentially steroid-responsive lung involvement, and malignant infiltrates were under-diagnosed. Complications associated with lung biopsies occurred in about 10% of patients who were highly selected based on platelet count, performance status, and goals of care. Given the lower diagnostic yield of lung biopsy in ICU patients, the risk–benefit ratio is not favourable; therefore, lung biopsy is rarely performed in critically ill immunocompromised patients with acute respiratory failure and lung infiltrates of unknown cause. However, minimally invasive CT-guided lung biopsies and transbronchial cryobiopsies are increasingly done. Studies to assess the timing of these minimally invasive biopsy techniques in this setting are warranted. The diagnostic yield should be better defined as the identification of a new diagnosis that was not detected by any other less invasive technique and that resulted in a change in treatment. Moreover, the risk–benefit ratio needs to be re-assessed. If these minimally invasive biopsy techniques are evaluated in a randomised controlled trial, control patients should receive empirical treatment for the most common lung biopsy diagnoses, namely, invasive fungal infection or steroid-responsive lung disease (panel 2).

### Oxygenation and ventilation strategies

The initial oxygenation and ventilation strategy aims to restore safe oxygenation, reduce the respiratory rate, alleviate the dyspnoea and respiratory distress, and improve patient comfort. Over the past two decades, studies have consistently shown higher mortality in immunocompromised patients who required IMV. Priority has, therefore, been given to avoidance of IMV by use of non-invasive oxygenation or ventilation devices (figure 6). However, failure of NIV13,41,100 or HFNO10 was associated with higher mortality,13 and two older studies even suggested that early IMV was associated with improved survival.101,102 Furthermore, because respiratory disease severity or associated organ dysfunctions are usually worse in intubated patients, determining whether the excess mortality in patients on IMV is due to the IMV itself or to the greater severity of the acute illness is difficult. In other words, a focus on avoiding intubation might not be effective, because the need for IMV might identify a group of patients with high disease severity.

Overall, five initial oxygenation methods are available for patients with hypoxaemic acute respiratory failure (figure 6). Guidelines from the European Respiratory Society and American Thoracic Society advocate the use of NIV. This recommendation is based mainly on a 2001 single-centre trial in 52 patients, in which mortality was 81% in the group assigned to standard oxygen, the highest ever reported in this setting (table 2). Another seminal trial in solid organ transplant recipients also

### Table 4: Studies reporting the results of surgical or post-mortem lung biopsies

| Study | Surgical | Post-mortem | Invasive fungal infections | Mycobacterial infections | Need for steroids or chemotherapy | Comments |
|-------|----------|-------------|-----------------------------|--------------------------|----------------------------------|----------|
| White et al (2000)94 | 63 | 0 | 8 (13%) | 6 (9.5%) | 47 (75%) | Complication rate 13%, lower diagnostic yield in neutropenic patients and patients on IMV, higher diagnostic yield if focal infiltrates |
| Gossot et al (2001)95 | 21* | 0 | 0 | 0 | 8 of 29 (26%) | 0 of 9 biopsies of residual mass in patients with lymphoma |
| Dai et al (2005)96 | 7 | 0 | 1 (14%) | 0 | 3 (43%) | All patients underwent lung biopsy for suspected invasive pulmonary aspergillosis |
| Kim et al (2002)97 | 31 | 0 | 17 (55%) | 1 | 12 (39%) | Complication rate 11%, lower diagnostic yield in patients on IMV |
| Sharma et al (2005)98 | 71 | 0 | 12 (17%) | 14 (20%) | 19 (27%) | All were adult bone marrow transplant recipients (39 allogeneic) |
| Zihlif et al (2005)99 | 62 | 0 | 14 (23%) | 0 | 31 (50%) | Complication rate 11%, lower diagnostic yield in patients on IMV |
| Gupta et al (2010)100 | 213 | 0 | 32 (15%) | 13 (6%) | 85 (40%) | Large or cavitary lesions or lung masses were more likely to yield a specific diagnosis |
| Sharma et al (2013)101 | 34† | 0 | 15 (44%) | NA | NA | Only haematology patients |
| Gay et al (2013)102 | 11 | 10 | 0 | 5 (24%) | 5 (24%) | Allogeneic bone marrow transplant recipients with biopsy-verified bronchiolitis obliterans |
| Uhling et al (2015)103 | 44 | 0 | 13 (29.5%) | NA | 4 (9%) | Bronchiolitis obliterans |

IMV=invasive mechanical ventilation. NA=not applicable. *8 CT-guided biopsies. †All CT-guided.
IMV and mortality rates were higher in the NIV group compared with the HFNO and standard oxygen groups. These results are consistent with studies reporting an increased risk of failure and mortality in patients receiving NIV for severe acute respiratory distress syndrome.41,75,79 Thus, these data raise concerns about the use of NIV in immunocompromised patients with hypoxaemic acute respiratory failure.

When first introduced, HFNO seemed a promising alternative to NIV. HFNO is easy to use and delivers humidified warmed oxygen, thereby allowing high flows by improving tolerability and comfort.104 HFNO improves oxygenation, lowers the respiratory rate, inspiratory effort, and maintains SpO2 ≥95%; or when standard oxygen fails to achieve these clinical goals.

When standard oxygen alone alleviates respiratory distress and maintains SpO2, ≥95%; or when standard oxygen fails to achieve these clinical goals.

Table 2: Unresolved issues and future directions in acute respiratory failure in patients with solid or haematological malignancies, solid organ transplant recipients, and patients taking immunosuppressive drugs

Update data on the prevalence of pulmonary involvement in immunocompromised patients

- Develop and implement multinational patient registries
- Analyse the severe forms of drug-related toxicity from targeted therapy, immunotherapy, and other new drugs
- Collect longer-term follow-up data to assess the true morbidity of acute respiratory failure

Define the best standard of care for immunocompromised patients with acute respiratory failure

- Monitor times to intensive care unit (ICU) admission, to treatment implementation, and to diagnosis
- Manage respiratory failure and associated organ dysfunctions according to the latest guidelines
- Find a balance between aggressive and non-beneficial care, and implement full-code intensive care in patients with a substantial hope of survival

Educate all stakeholders to avoid delays in ICU management

- Provide information on outcomes according to oxygen needs
- Explain how delayed ICU admission leads to increased mortality
- Encourage clinicians to assess the pre-test probability of each acute respiratory failure cause and start the corresponding treatments early

Develop a minimal early diagnostic investigation that applies to all patients, combined with targeted diagnostic strategies for patients at risk for specific diseases

- Search for bacterial and fungal infections (putum examination, blood cultures), viral infection (multiplex PCR on nasopharyngeal aspirates or swabs), and cardiogenic pulmonary oedema; evaluate the extent to which the underlying condition and its treatments may affect the lungs; obtain imaging data in all patients
- Apply specific clinical algorithms and perform targeted non-invasive or minimally invasive diagnostic tests in patients at risk for specific diseases (Pneumocystis pneumonia, invasive aspergillosis, mycobacterial disease, etc)
- Identify situations in which more invasive tests may be required

Evaluate omics technologies on non-invasive samples

- Apply genomics, metagenomics, proteomics, metabolomics, and transcriptomics on samples that can be collected easily from patients with tachypnoea and hypoxaemia
- Use clinical algorithms and evaluate their ability to confirm the diagnosis in high-risk patients or to rule out the diagnosis in low-risk patients
- Assess whether the use of these technologies can result in improved clinical outcomes

Provide convincing data regarding the superiority of non-invasive ventilation or high-flow nasal oxygen therapy

- When standard oxygen alone alleviates respiratory distress and maintains SpO2, ≥95%; or when standard oxygen fails to achieve these clinical goals
- Clarify whether patients who are intubated after failed non-invasive ventilation or high-flow nasal oxygen therapy would have had better outcomes if they had received earlier intubation and lung-protective ventilation
- Define consensual intubation criteria, as the need for invasive mechanical ventilation is an important outcome measure

Develop a multinational network to improve the management of immunocompromised patients with acute respiratory failure

- To define a non-invasive diagnostic and therapeutic strategy that is readily feasible at many locations and to demonstrate, using cohort studies and randomised controlled trials, how this strategy translates into improved outcomes
- To validate clinical algorithms that help identify patients at low vs high risk for a given disease
- To develop and implement multicentre basic and translational research
- To promote education, update guidelines, and establish patient-centred outcome measures
and work of breathing, and reduces minute ventilation at a constant PaCO₂.¹⁰⁵ HFNO also increases end-expiratory lung volume and dynamic lung compliance.¹⁰⁵ These physiological effects are even more pronounced when increasing flow rates are delivered.¹⁰⁶ However, in a randomised controlled trial in 310 unselected patients with hypoxaemic acute respiratory failure and a PaO₂/FiO₂ ratio ≤300 mm Hg,¹⁰⁷ the number of patients requiring intubation was not significantly reduced with HFNO compared with NIV or standard oxygen. However, the number of ventilator-free days on day 28 was significantly higher with HFNO, and the hazard ratio for day-90 mortality was lower with HFNO.

Five studies evaluated the feasibility and safety of HFNO in immunocompromised patients with acute respiratory failure. In a retrospective single-centre study of 45 patients with haematological malignancies (half were bone marrow transplant recipients,¹⁰⁸ half had recently received systemic chemotherapy, and 42% were neutropenic), HFNO allowed recovery without intubation.

Figure 6: Nine oxygenation and ventilation methods

Standard oxygen can be administered through a wide array of devices. Low-flow oxygen systems comprise a nasal cannula (or nasal catheter; A) providing supplemental oxygen at flows below the total minute ventilation, leading to oxygen dilution with ambient air and lowering the inspired oxygen concentration. A standard nasal cannula delivers an inspiratory FiO₂ of 0.24–0.44 at supply flows 1–8 L/min, depending on respiratory rate and tidal volume. A humidification device is recommended for flows >4 L/min. Reservoir masks (B) can deliver FiO₂ values of 0.40–0.60 at 5–10 L/min. The reservoir system (~100–300 cm³) stores oxygen. A flow rate >5 L/min must be set to ensure the washout of exhaled gas and avoid CO₂ retention. The non-rebreathing facemask (C) may deliver up to 0.90 FiO₂, at flow settings >10 L/min. It should be used only for short periods, as humidification is difficult and there is also a risk of CO₂ retention if the mask’s reservoir bag is allowed to collapse on inspiration. Lastly, the Venturi system (D) mixes oxygen with room air (humidification is not necessary) and provides an accurate and constant FiO₂, despite variations in respiratory rate and tidal volume. It is employed when concern arises about CO₂ retention or when the respiratory drive is inconsistent. High-flow oxygen therapy through nasal prongs or cannulas (high-flow nasal oxygen therapy; E) supplies an exact FiO₂ (up to 1) at a flow equal to or greater than the patient’s inspiratory flow demand. Nasal oxygen is administered at a flow rate of up to 60 L/min. It is warmed to body temperature and saturated to full humidity by molecular humidification. Non-invasive positive-pressure ventilation provides ventilator support without an endotracheal tube, using an oronasal (F) or total face (G) mask or a helmet (H). The main non-invasive ventilation mode used in hypoxaemic acute respiratory failure is pressure support; continuous positive airway pressure and bi-level positive airway pressure are used less often. Finally, invasive mechanical ventilation (I) uses a tracheal tube inserted into the trachea under general anaesthesia and a neuromuscular-blocking drug. The tube is then secured to the face or neck and connected to a ventilator. In patients with hypoxaemic acute respiratory failure, intubation and invasive mechanical ventilation are used after failure of standard oxygen and, in some cases, of the aforementioned non-invasive options. FiO₂ = fraction of inspired oxygen.
in one-third of the patients. The hospital mortality rate was 13·3% when HFNO was successful and 86·7% when HFNO failed. The HFNO failure rate was only 15% in a single-centre study of 183 patients with solid tumours, but was 80% in a study of 56 haematology patients. A phase 2 trial in 30 patients with advanced cancer and persistent dyspnoea compared HFNO with biphasic positive airway pressure. Oxygen saturation improved only with HFNO, whereas both treatments provided similar improvements in dyspnoea and respiratory rate. In 37 lung transplant recipients with acute respiratory failure, HFNO proved feasible and safe and decreased the absolute risk of intubation by 29·8%, with a number-needed-to-treat to avoid one intubation of 3.

Although no results from trials specifically assessing HFNO in immunocompromised patients with hypoxaemic acute respiratory failure are available, six studies compared HFNO with other oxygenation or ventilation strategies in this setting (table 2). In a retrospective cohort of 178 patients with cancer and acute respiratory failure, 76 (43%) patients received NIV plus HFNO, 74 (42%) NIV plus standard oxygen, 20 (11%) HFNO alone, and 8 (4%) standard oxygen alone. The combination of NIV and HFNO was associated with lower mortality rates (37% vs 52% in the other patients, p=0·04) and was independently associated with higher day-28 survival. In a post-hoc analysis of data from the INVICTus randomised controlled trial of early NIV in immunocompromised patients with acute respiratory failure, neither the intubation rate nor day-28 mortality differed significantly between the HFNO arm and the standard oxygen arm. In the post-hoc analysis of the trial by Frat and colleagues, outcomes were compared across standard oxygen, NIV, and HFNO. Although NIV was associated with increased need for intubation and higher mortality, neither parameter differed significantly between the 30 patients assigned to standard oxygen and the 26 patients assigned to HFNO. In a retrospective study of 115 immunocompromised patients with acute respiratory failure, the proportion of patients that required intubation (55% vs 35%) and mortality (40% vs 20%) were higher with NIV than with HFNO. In the Efraim multicentre, multinational, prospective cohort study of 1611 immunocompromised patients, 915 patients were not intubated on ICU admission and received standard oxygen, HFNO, NIV, or NIV plus HFNO. Hospital mortality was not affected by the initial oxygenation or ventilation management. There was a non-significant trend towards reduced intubation in patients given HFNO. In a retrospective study of 38 kidney recipients, the number of ventilator-free days on day 28 was significantly higher in the HFNO group than in the NIV group. The results of two trials of HFNO focusing specifically on immunocompromised adults with acute respiratory failure (NCT02739451 and NCT02978300) are expected to be available in a few months. HFNO has not yet been properly evaluated regarding its ability to assist diagnostic procedures such as bronchoscopy with bronchoalveolar lavage and bronchial or transbronchial biopsies.

Changes in the initial oxygenation and NIV strategy are unlikely to translate into improved survival. The response of patients to standard oxygen, HFNO, or NIV should be carefully assessed. If the initial strategy of standard oxygen, NIV, or HFNO lowers the respiratory rate and minute ventilation then it should be continued and continuously reevaluated. If the tachypnoea and high respiratory drive persist, the risk of intubation is very high and it is reasonable to evaluate the potential benefits of avoiding delayed intubation and adding self-inflicted lung injury to the initial pulmonary insult. Early intubation has been associated with improved survival in haematology patients. Studies of early intubation in patients with a persistently high respiratory drive despite the initial oxygenation strategy are warranted.

Conclusion

In summary, acute respiratory failure is a common and often fatal event in immunocompromised patients that raises major diagnostic and therapeutic challenges. In the near future, with the use of more intensive therapeutic regimens designed to cure cancer, induce transplant tolerance, or control autoimmune and inflammatory diseases in ever older and frailer patients, the incidence of acute respiratory failure against a background of immunodeficiency can be expected to increase. Moreover, the expanding use of targeted therapies and immunotherapies will lead to a growing burden of toxicity and infection during the increasing life spans of these populations. Our knowledge of the effects of acute respiratory failure needs to be improved by longer-term follow-up studies. Multinational registries must be developed to analyse the effect of new drugs and update clinicians on future trends in the incidence of acute respiratory failure and in the use of intensive care for patients with acute respiratory failure. Targets for improving survival, such as early ICU admission and the early identification or treatment of the cause of acute respiratory failure, require evaluation in large randomised controlled trials. Patients with substantial life expectancy and who agree to undergo ICU management should be offered unrestricted access to diagnostic and therapeutic strategies. The greatest challenges are the identification of patients at high risk for specific diagnoses, earlier treatment of acute respiratory failure causes, and selection of the least invasive diagnostic tests. The non-invasive approach is promising but still needs to be refined and updated. Combining clinical algorithms and sophisticated tests, such as genomics, metagenomics, proteomics, or transcriptomics, on non-invasive samples to document or rule out infections will be a major advance only if the results include survival benefits, shorter ICU and hospital stay lengths, reduced costs, and improved patient-reported outcomes. Given that the initial oxygenation and NIV strategy is unlikely to be associated with survival, assessing the patient’s
response to standard oxygen, HFNO, or NIV within 1–4 h following ICU admission might be the best approach. Patients who improve, whether quickly or slowly, can then be differentiated from those with persistent tachypnoea, high respiratory drive, and increasing oxygen needs, for whom avoiding late intubation might have lung-protective effects.

Declaration of interests
EA reports personal fees from Gilead, Alexion, Baxter, and Astellas and a grant from MSD. AD reports personal fees from Medtronic, Philips, Resmed, Fisher & Paykel, Baxter, and Hamilton. All other authors declare no competing interests.

Acknowledgments
We thank Olivier Lescale for the illustrations in figure 6.

References
1 Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA 2016; 316: 1567–48.
2 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.
3 Israni AK, Zaun D, Rosendale JD, Schaffhausen C, Snyder JJ, Kasiske BL, OPTN/SRTR 2016 annual data report: deceased organ donation. Am J Transplant 2018; 18 (suppl 1): 434-63.
4 Weyand CM, Goronyz J. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 2014; 371: 50–57.
5 Azoulay E, Thiéry G, Chevret S, et al. The prognosis of acute respiratory failure in critically ill cancer patients. Medicine (Baltimore) 2004; 83: 360–70.
6 Orasch C, Weiser M, Mertz D, et al. Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 45: 521–26.
7 Bos MMEM, Verburg IWM, Dumiati L, et al. Intensive care admission of cancer patients: a comparative analysis. Cancer Med 2015; 4: 966–76.
8 Lee D-S, Suh GY, Ryu J-A, et al. Effect of early intervention on long-term outcomes of critically ill cancer patients admitted to ICUs. Crit Care Med 2015; 43: 1419-48.
9 Azoulay E, Mokart D, Lambert J, et al. Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med 2010; 182: 1038–46.
10 Gruson D, Vargas F, Hilgert G, et al. Predictive factors of intensive care unit admission in patients with haematological malignancies and pneumonia. Intensive Care Med 2004; 30: 965–71.
11 Lemiale V, Mokart D, Resche-Rigon M, et al. Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA 2015; 314: 1711–19.
12 Frat J-P, Ragot S, Girault C, et al. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomized trial. Lancet Respir Med 2016; 4: 646–52.
13 Azoulay E, Pickkers P, Snars M, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efrain multinational prospective cohort study. Intensive Care Med 2017; 43: 1808–19.
14 Azoulay E, Mokart D, Pène F, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 2013; 31: 2830–48.
15 Lemiale V, Resche-Rigon M, Mokart D, et al. Acute respiratory failure in patients with hematological malignancies: outcomes according to initial ventilation strategy. A groupe de recherche respiratoire en réanimation onco-hématologique (Grrr-OH) study. Ann Intensive Care 2015; 5: 28.
16 Lemiale V, Lambert J, Canet E, et al. Identifying cancer subjects with acute respiratory failure at high risk for intubation and mechanical ventilation. Respir Care 2014; 59: 1517–23.
17 Mokart D, Lambert J, Schnell D, et al. Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma 2013; 54: 1724–29.
18 Garcia JR, Lei X, Wierda W, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc 2011; 10: 432–40.
19 Chauvi D, Legrand O, Roche N, et al. Incidence and prognostic value of respiratory events in acute leukemia. Leukemia 2004; 18: 670–75.
20 Moreau A-S, Lengeline E, Seguin A, et al. Respiratory events at the earliest phase of acute myeloid leukemia. Leuk Lymphoma 2014; 55: 2556–63.
21 Azoulay E, Freux F, Moreau D, et al. Acute monocytic leukemia presenting as acute respiratory failure. Am J Respir Crit Care Med 2003; 167: 1129–33.
22 Specchia G, Pastore D, Carluccio P, et al. Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. Leuk Lymphoma 2003; 44: 97–101.
23 Rossini F, Verga M, Pioletti P, et al. Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline-containing regimens. Haematologica 2000; 85: 1255–60.
24 Puig N, De La Rubia J, Jarque I, et al. Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation. Leuk Lymphoma 2007; 48: 2167–74.
25 Alessa B, Abdullai RM, Kremers WK, Hogan WJ, Litow MR, Peters SG. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. Chest 2012; 144: 420–50.
26 Bergeron A, Chevret S, Peffault de Latour R, et al. Noninfectious lung complications after allogeneic hematopoietic stem cell transplantation. Eur Respir J 2018; 51: 1700617.
27 Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer R. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 223–29.
28 Meyer E, Beyersmann J, Bertz H, et al. Risk factor analysis of blood stream infection and pneumonia in neutropenic patients after peripheral blood stem-cell transplantation. Bone Marrow Transplant 2007; 39: 173–78.
29 Rolston KV, Neshet L. Post-obstructive pneumonia in patients with cancer: a review. Infect Dis Ther 2018; 7: 29–38.
30 Cupp J, Cuculova E, Poniewierski MS, Dale DC, Lyman GH, Crawford J. Analysis of factors associated with in-hospital mortality in lung cancer chemotherapy patients with neutropenia. Clin Lung Cancer 2018; 19: e163–69.
31 Taghiyan AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001; 93: 1806–11.
transplant recipients: a multicenter study. Crit Care 2015; 13 (suppl 3): 22–25.

Canet E, Osman D, Lambert J, et al. Acute respiratory failure in kidney transplant recipients: a multicenter study. Crit Care 2011; 15: R91.

Ulus A, Kaplan S, Zeyneloglu P, Torgay A, Pirat A, Haberal M. Acute respiratory failure in renal transplant recipients: a single intensive care unit experience. Exp Clin Transplant 2013; 13 (suppl 3): 44–47.

Rabbat A, Chauvi D, Montani D, et al. Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol 2005; 129: 350–57.

Rashid S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 2018; 6: 472–78.

Azoulay E, Lermiaie V, Mokart D, et al. Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med 2014; 40: 1016–14.

Adda M, Coquet I, Darmon M, Thiery G, Schlemmer B, Azoulay E. Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Crit Care Med 2008; 36: 2766–72.

Frat J-P, Ragot S, Coudroy R, et al. Predictors of intubation in patients with acute hypoxemic respiratory failure treated with a noninvasive oxygenation strategy. Crit Care Med 2017; 46: 208–15.

Azoulay E, Lermiaie V, Mokart D, et al. High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial. Trials 2018; 19: 157.

Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. Am J Respir Crit Care Med 2017; 195: 438–42.

Roca O, Messika J, Carbalit B, et al. Predicting success of high-flow nasal cannula in patients with hypoxic respiratory failure: the utility of the ROX index. J Crit Care 2016; 35: 200–05.

Chu DK, Kim LH-Y, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet 2018; 391: 1031–705.

Gratina GR, Antonelli M, Conti G, et al. Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. Crit Care Med 2011; 39: 2232–9.

Azoulay E, Pene F, Darmon M, et al. Managing critically ill hematology patients: time to think differently. Blood Rev 2015; 29: 159–67.

Soares M, Toffart A-C, Timsit J-F, et al. Intensive care in patients with lung cancer: a multinational study. Ann Oncol 2014; 25: 1829–35.

Martos-Benitez FD, Soto-Gaczia A, Gutierrez-Noyola A. Clinical characteristics and outcomes of cancer patients requiring intensive care unit admission: a prospective study. J Cancer Res Clin Oncol 2018; 144: 717–23.

Puny K, McLoone P, Quissin T, Kinsella J, Morrison D. Survival in solid cancer patients following intensive care unit admission. Intensive Care Med 2014; 40: 1409–28.

Zampieri FG, Bozza FA, Morealez GM, et al. The effects of performance status one week before hospital admission on the outcomes of critically ill patients. Intensive Care Med 2017; 43: 39–47.

Azoulay E, Schlemmer B. Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med 2006; 32: 808–22.
76 Aroulay E, Mokart D, Rablat A, et al. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. *Crit Care Med* 2008; 36: 100–07.

77 Wolflarth P, Beutel G, Lehiede P, et al. Noninvasive ventilation in hematoologic and oncologic patients (iCHOP): caring for critically ill immunocompromised patients multinational network (NINE-I). *Crit Care Med* 2017; 45: e500–07.

78 Schmidt M, Schellongowski P, Patroniti N, et al. Six-month outcome of immunocompromised severe acute respiratory distress syndrome patients rescued by extracorporeal membrane oxygenation. An international multicenter retrospective study. *Am J Respir Crit Care Med* 2018; 197: 1297–307.

79 Antonelli M, Conti G, Buß M, et al. Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation: a randomized trial. *JAMA* 2006; 295: 233–41.

80 Lemièvre V, Resche-Rigon M, Mokart D, et al. High-flow nasal cannula oxygenation in immunocompromised patients with acute hypoxemic respiratory failure: a groupe de recherche respiratoire en réanimation onco-hématologique study. *Crit Care Med* 2017; 45: e274–80.

81 Mokart D, Grace C, Chow-Chine L, et al. High-flow oxygen therapy in cancer patients with acute respiratory failure. *Intensive Care Med* 2015; 41: 2008–10.

82 Coudroy R, Jarret A, Petau P, Robert R, Prat J-P, Thille AW. High-flow nasal cannula oxygen therapy versus noninvasive ventilation in immunocompromised patients with acute respiratory failure: an observational cohort study. *Ann Intensive Care* 2016; 6: 45.

83 Tu G, He H, Yin K, et al. High-flow nasal cannula versus noninvasive ventilation for treatment of acute hypoxic respiratory failure in renal transplant recipients. *Transplant Proc* 2017; 49: 1325–30.

84 Lewandowska DW, Schreiber PW, Schuurmans MM, et al. Metagenomic sequencing complements routine diagnostics in identifying viral pathogens in lung transplant recipients with unknown etiology of respiratory infection. *Placenta* 2017; 12: e017740.

85 White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. *Am J Respir Crit Care Med* 2000; 161: 723–29.

86 Gossot D, Girard P, de Kerviler E, et al. Thorascopy or CT-guided biopsy for residual intrathoracic masses after treatment of lymphoma. *Chest* 2001; 120: 289–94.

87 Dai MS, Lee SC, Ho CL, Chen YC, Kao WY, Chao TY. Impact of open lung biopsy for unexplained pulmonary infiltrates in patients with hematologic malignancies. *Am J Hematol* 2001; 68: 87–90.

88 Kim K, Lee MH, Kim J, et al. Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. *Am J Hematol* 2002; 71: 75–79.

89 Sharma S, Nadrous HF, Peters SG, et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. *Chest* 2005; 128: 1385–92.

90 Zilhif M, Khanchandani G, Ahmed HP, Souhani AO. Surgical lung biopsy in patients with hematologic malignancy or hematopoietic stem cell transplantation and unexplained pulmonary infiltrates: improved outcome with specific diagnosis. *Am J Hematol* 2005; 78: 94–99.

91 Gupta S, Sulentenus M, Romaguera JE, et al. CT-guided percutaneous lung biopsies in patients with hematologic malignancies and associated radiation treatment. *Am J Radiol Oncol* 2010; 28: 75–81.

92 Sharma SK, Kumar S, Singh AK, et al. Feasibility and outcome of CT-guided lung biopsy in patients with hematological diseases and suspected fungal pneumonia. *J Infect Dev Ctries* 2013; 7: 748–52.

93 Gay J, Lemiere V, Meignin V, et al. Diagnostic contribution from pulmonary biopsies in hematology patients with acute respiratory failure from undetermined etiology. *Minerva Anestesiol* 2013; 79: 853–60.

94 Uhlving HH, Andersen CB, Christensen IJ, et al. Biopsy-verified bronchiolitis obliterans and other noninfectious lung pathologies after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2015; 21: 531–38.

95 Contjean A, Lemiere V, Resche-Rigon M, et al. Increased mortality in hematologic malignancy patients with acute respiratory failure from undetermined etiology: a groupe de recherche en réanimation respiratoire en onco-hématologique (Grrr-OH) study. *Ann Intensive Care* 2016; 6: 102.

96 de Hemetpinen Q, Remmelink M, Brimouille S, Salmon I, Vincent J-L. ARDS: a clinicopathological confrontation. *Chest* 2009; 135: 944–49.

97 de Bazelaire C, Coffin A, Cohen-Zarade S, et al. CT-guided biopsies in lung infections in patients with haematological malignancies. *Diagn Interv Imaging* 2013; 94: 202–15.

98 Nsair A, Anghilieri M, Carenfello G, et al. Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. *Haematologica* 2003; 88: 1405–09.

99 Fruchter O, Fridei L, Rosengarten D, Rahman NA, Kramer MR. Transbronchial cryobiopsy in immunocompromised patients with pulmonary infiltrates: a pilot study. *Lung* 2013; 191: 615–24.

100 Dhooria S, Sehgal IS, Aggarwal AN, Behera D, Agarwal R. Diagnostic yield and safety of cryoprobe tranbronchial lung biopsy in diffuse parenchymal lung diseases: systematic review and meta-analysis. *Respir Crit Care Med* 2016; 61: 700–12.

101 Rochweg B, Broomhead L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J* 2017; 50: 1602462.

102 Grisnta GR, De Gaudio R, Mazzon D, Curtis JR. End of life care in Italian intensive care units: where are we now? *Minerva Anestesiol* 2011; 77: 911–20.

103 Depuydt PO, Benoist DD, Vandewoude KH, Decruyenaere JM, Colardyn FA. Outcome in noninvasively and invasively ventilated hematologic patients with acute respiratory failure. *Chest* 2004; 126: 1299–306.

104 Neuschwander A, Lemiere V, Darmon M, et al. Noninvasive ventilation during acute respiratory distress syndrome in patients with cancer: trends in use and outcome. *J Crit Care* 2017; 38: 295–99.

105 Bellasi G, Laffey JG, Plam T, et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE study. *Am J Respir Crit Care Med* 2017; 195: 67–77.

106 Papazian L, Corley A, Hess D, et al. Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. *Intensive Care Med* 2016; 42: 1336–49.

107 Mauri T, Turri C, Eronia N, et al. Physiologic effects of high-flow nasal cannula in acute hypoxic respiratory failure. *Am J Respir Crit Care Med* 2017; 195: 1287–1303.

108 Mauri T, Alban L, Turri C, et al. Optimum support by high-flow nasal cannula in acute hypoxic respiratory failure: effects of increasing flow rates. *Intensive Care Med* 2017; 43: 1543–63.

109 Frat J-P, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxic respiratory failure. *N Engl J Med* 2015; 372: 2183–96.

110 Lee HY, Rhee CK, Lee JW. Feasibility of high-flow nasal cannula oxygen therapy for acute respiratory failure in patients with hematologic malignancies: a retrospective single-center study. *J Crit Care* 2015; 30: 773–77.

111 Epstein AS, Hartridge-Lambert SK, Ramaker JS, Voigt LP, Portlock CS. Humidified high-flow nasal oxygen utilization in patients with cancer at Memorial Sloan-Kettering Cancer Center. *J Palliat Med* 2011; 14: 835–39.

112 Harada K, Kurousawa S, Hino Y, et al. Clinical utility of high-flow nasal cannula oxygen therapy for acute respiratory failure in patients with hematological disease. *SpringerPlus* 2016; 5: 512.

113 Hui D, Morgado M, Chisholm G, et al. High-flow oxygen and bilevel positive airway pressure for persistent dyspnea in patients with advanced cancer: a phase II randomized trial. *J Pain Symptom Manage* 2013; 46: 463–73.

© 2018 Elsevier Ltd. All rights reserved.